CMC Biologics Announces Agreement with Daiichi Sankyo to Develop and Manufacture Antibodies
Advertisement
CMC Biologics announces the execution of an agreement with Daiichi Sankyo Co., Ltd. to provide process development support and manufacture of several clinical-stage antibodies over a three-year period. The two companies have recently begun work on thier first joint project at CMC Biologics´Bothell manufacturing facility. Specific terms of the agreement were not disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous